Vaxart Inc (VXRT)

[conix]

Vaxart starts enrollment in early-stage norovirus boosting regimen study

May 04, 2021 9:31 AM ETVaxart, Inc. (VXRT)
By: Aakash Babu, SA News Editor

Vaxart (VXRT +16.3%) announces that it has enrolled the first subject in a Phase 1b boosting regimen trial of its norovirus vaccine candidate.

The Phase 1b study is designed to enroll 30 subjects aged 18 to 55 years old, with endpoints being safety and immunogenicity.

Subjects will be randomized into 3 cohorts: Cohort 1 will receive the vaccine candidate on day 1 and week 4; Cohort 2 will receive the vaccine candidate on day 1 and week 8; Cohort 3 will receive the vaccine candidate on day 1 and week 12.

Norovirus is a potentially fatal illness that affects around 20M Americans annually.

The booster regimen trial is the second of four Vaxart norovirus trials that are ongoing or are planned for 2021.

The company is also scheduled to initiate an age escalation trial in subjects over 65 years old and plans to launch a Phase 2 challenge study later this year.

New data obtained from Vaxart's Phase I COVID-19 trial suggests that its oral coronavirus vaccine, VXA-CoV2-1, triggers mucosal immunity, includes both S and N SARS-Cov-2 proteins, and has broad cross-coronavirus activity, the company had said on Monday.